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C57BL/6 (B6) mice are genetically highly susceptible to chronic type II Toxoplasma gondii infections that
invariably cause lethal toxoplasmic encephalitis. We examined the ability of an attenuated type I vaccine strain
to elicit long-term immunity to lethal acute or chronic type II infections in susceptible B6 mice. Mice
immunized with the type I cps1-1 vaccine strain were not susceptible to a lethal (100-cyst) challenge with the
type II strain ME49. Immunized mice challenged with 10 ME49 cysts exhibited significant reductions in brain
cyst and parasite burdens compared to naive mice, regardless of the route of challenge infection. Remarkably,
cps1-1 strain-immunized B6 mice chronically infected with ME49 survived for at least 12 months without
succumbing to the chronic infection. Potent immunity to type II challenge infections persisted for at least 10
months after vaccination. While the cps1-1 strain-elicited immunity did not prevent the establishment of a
chronic infection or clear established brain cysts, cps1-1 strain-elicited CD8 immune T cells significantly
inhibited recrudescence of brain cysts during chronic ME49 infection. In addition, we show that uracil
starvation of the cps1-1 strain induces early markers of bradyzoite differentiation. Collectively, these results
suggest that more effective immune control of chronic type II infection in the genetically susceptible B6
background is established by vaccination with the nonreplicating type I uracil auxotroph cps1-1 strain.
Toxoplasma gondii is a common and significant obligate in-
tracellular pathogen of humans and animals. There are three
clonal types that exist which are also thought to be derived
when T. gondii acquired oral infectivity (50). Virulence in mice
is strain specific where type I clones are universally virulent,
type II clones are of intermediate virulence, and type III clones
are avirulent. Ingestion of contaminated food sources is the
most common route of human infection, resulting in systemic
disease that can be divided into two stages: the acute dissem-
inating tachyzoite stage and the chronic encysted bradyzoite
stage (12). Recrudescent infections arising from reactivation of
preexisting chronic latent cyst stages are particularly severe in
the context of immune deficiency such as AIDS (38), and
improved treatments and the development of vaccines to re-
duce disease burden are important therapeutic objectives.
Strategies with the potential to eradicate the latent cyst stages
present in already-infected individuals could be helpful but,
unfortunately, the biology of cyst development, as well as the
immune control mechanisms of latent stages, are relatively
poorly understood at this time. Clearly, CD8 T cells and
gamma interferon (IFN-) are significant effectors in mediat-
ing resistance to acute and chronic T. gondii infection (17, 19).
Numerous studies have evaluated responses to vaccines
based on protein or DNA components of T. gondii with various
degrees of success (1, 2, 4, 5, 9, 11, 22, 24, 25, 28, 36, 37, 40, 44,
46). Virulent parasite strains, as well as attenuated T. gondii
strains, have been paramount in dissecting the immunobiology
of host response in regard to understanding adaptive immune
responses that may be helpful in vaccine design. Dense granule
protein 6 (GRA6), GRA4, and rhoptry bulb protein 7 (ROP7)
were recently identified as parasite antigens possessing a H-2Ld-
restricted major histocompatibility complex class I (MHC-I)
epitope that correlates with stage-specific expression and re-
sistance to lethal chronic type II infections in the H-2Ld back-
ground (BALB/c). These data further define a potential mo-
lecular basis for genetic susceptibility to lethal type II chronic
infections in the C57BL/6 H-2b MHC-I-restricted background
(6, 16). Vaccine models using either live attenuated parasites,
such as type I strain ts-4, or irradiated tachyzoites, have had the
greatest success in providing complete protection against lethal
type I challenges. These studies also report more significant
reductions in type II cyst burdens than component vaccines or
whole-dead parasite vaccines (42, 48, 53, 54). However, live
parasite-based vaccines such as strain ts-4 are still slowly rep-
licating and retain a significant potential for virulence in the
immunocompromised host. Furthermore, immune protection
elicited by strain ts-4 is not long-lasting and significantly de-
creases within months after immunization (27).
From the same parental RH strain that strain ts-4 was de-
veloped (45), our laboratory developed a fully attenuated non-
replicating type I cps1-1 strain that exhibits a severe uracil
auxotrophy. The cps1-1 strain in a single immunization elicits
complete immune protection and is able to clear high lethal
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dose virulent type I infection (14). Significantly, this highly
attenuated strain is completely avirulent at extreme doses in
immunocompromised hosts, such as in Tyk2/ mice (49),
which cannot control inflammation, and also in IFN-/ mice
(14, 20). The cps1-1 strain elicits potent Th1 immunity to lethal
type I challenge infection after immunization of BALB/c,
C57BL/6, Tyk2/ (C57BL/6), or MyD88/ (C57BL/6) mice
(13, 14, 20, 49, 51, 56). Immunity to lethal type I challenge
infection induced by the cps1-1 strain is dependent on CD8 T
cells (20), local production of IFN- (20), and interleukin-12
(IL-12) p70 (20, 51, 56). Remarkably, the potent immunity
elicited by vaccination with the cps1-1 strain does not require
systemic IFN- (20).
We show here that the immunity induced in C57BL/6 mice
after vaccination with the cps1-1 strain provides a surprisingly
effective and complete protection from a lethal oral or intra-
peritoneal (i.p.) challenge infection of type II cysts from the
ME49 strain. We address the durability of cps1-1 strain-in-
duced immunity to lethal type II cyst challenge infection by
different routes and find that immunization with the cps1-1
strain provides long-term protective immunity to lethal type II
challenge. Vaccination with the cps1-1 strain also markedly
reduces the cyst burden and protects susceptible C57BL/6 mice
from succumbing to chronic infection. CD8 immune T cells
elicited by vaccination with the cps1-1 strain prevent cyst re-
crudescence during chronic infection.
MATERIALS AND METHODS
Mice. Adult 6- to 8-week-old C57BL/6 (B6) mice were obtained from the
National Cancer Institute and mice were maintained in Tecniplast Seal Safe
mouse cages on vent racks at the Dartmouth-Hitchcock Medical Center mouse
facility. All mice were cared for and handled according to the Animal Care and
Use Program of Dartmouth College using National Institutes of Health-ap-
proved institutional animal care and use committee guidelines.
Tachyzoite culture and immunization with the cps1-1 strain. Tachyzoites of
the attenuated cps1-1 strain were obtained by uracil supplemented tissue culture
(14). Tachyzoites were isolated from freshly lysed human foreskin fibroblast
(HFF) monolayers by filtration through 3.0-m-pore-size Nucleopore mem-
branes, washed with phosphate-buffered saline (PBS), centrifuged, and then
resuspended in PBS at defined numbers after determination of the tachyzoite
concentration using a hemacytometer. The viability of tachyzoite preparations
was tested in plaque assays to confirm that 30 to 50% of tachyzoites were
infectious. Mice were immunized with 106 freshly isolated tachyzoites of the
cps1-1 strain twice 14 days apart. At 1 or 10 months after final immunization, the
mice were infected i.p. or perorally (i.g.) via gavage needle with either 10 or 100
brain-derived cysts of the ME49 strain.
ME49 cyst maintenance, isolation, and enumeration. Brain cysts of the strain
ME49 were obtained by continuous passage every 4 to 5 weeks in B6 mice
infected i.p. with 10 cysts. Brains from mice infected with ME49 were harvested
and homogenized by using a Dounce homogenizer in 2 ml of sterile 1 PBS.
Cysts were then counted by examining 10 l of the brain homogenate under a
coverslip using light microscopy under 40 magnification. Total cyst numbers
were determined per brain based on counting 5 to 50 slides prepared from each
brain homogenate.
Adoptive transfer of total splenocytes and purified T-cell subsets. Spleens
from cps1-1 strain-immunized or naive B6 mice were harvested and splenocytes
released by grinding the spleen through a 70-m-pore-size nylon screen in 5 ml
of Hanks balanced salt solution. Splenocytes were pelleted then subject to eryth-
rocyte lysis for 3 min at room temperature with sterile ACK buffer prepared in
house using 0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2 EDTA in distilled
H2O. Splenocytes were then washed extensively in sterile PBS, and live cells were
identified via trypan blue exclusion and enumerated by using a hemacytometer.
Then, 5  107 whole naive strain or cps1-1 strain immune splenocytes were then
transferred to chronically infected mice via tail vein injection. Separately, from
naive or cps1-1 strain immune splenocytes, purified CD4 and CD8 T cells
were isolated by using EasySep positive selection (Stem Cell Technologies).
Either 9  106 purified CD4 T cells, 4.5  106 purified CD8 T cells, or a
combination of 9  106 CD4 and 4.5  106 CD8 T cells were injected via tail
vein injection into chronically infected recipient mice.
Parasite burden measured by quantitative real-time PCR. Infected animals
were euthanized via CO2 overdose, and brain tissue was harvested and flash
frozen in liquid nitrogen. DNA was extracted from the entire organ by using a
DNeasy tissue kit (Qiagen, Inc., Germantown, MD), and samples were pooled.
Amplification of parasite DNA from 400 ng of purified tissue DNA was per-
formed using primers specific for the T. gondii B1 gene at 10 pmol of each per
reaction (29, 31) (Integrated DNA Technologies, Coralville, IA) and amplified
by real-time PCR using SMartMix HM (Cepheid, Sunnyvale, CA) on a Cepheid
Smart Cycler. Each reaction contained one lyophilized SMartMix HM bead and
SYBR green I (Cambrex BioScience, Inc., Rockland, ME). Known parasite
DNA equivalents were used to establish a standard curve, and then parasite
numbers in tissue samples were calculated via extrapolation from the standard
curve.
Immunohistochemistry of the cps1-1 tachyzoite-to-bradyzoite differentiation.
HFF monolayers were infected with the cps1-1 strain in the presence or absence
of uracil for 2 days, and immunohistochemistry analysis of infected HFF mono-
layers was performed (15). Briefly, confluent HFF cultures on glass coverslips
were infected with tachyzoites and then fixed with Histochoice tissue fixative
(Amresco) as specified by the manufacturer. Fixed infected cells were treated in
0.2% Triton X-100 for 20 min and blocked with 3% bovine serum albumin
overnight. Infected HFF cells on coverslips were incubated with appropriate
dilutions of primary antibody or biotinylated Dolichos biflorus lectin (DBA;
Vector Laboratories) for 90 min at 37°C, washed, and incubated with the sec-
ondary antibody or Strepavidin-Alexa 568, respectively. Monospecific polyclonal
rabbit antibodies (immunoglobulin G) to SAG1 (43) were used and stained with
anti-rabbit secondary antibody coupled to Alexa 488 (Molecular Probes). Bio-
tinylated DBA was stained by using streptavidin-Alexa 568 (Molecular Probes)
(32). Coverslips were mounted by using Vectashield (Vector Laboratories) or a
SlowFade Light Antifade kit with DAPI (4,6-diamidino-2-phenylindole) for
staining nucleic acid (Molecular Probes). Images were captured by using a Zeiss
AxioPhot upright photomicroscope with a slow-scan, cooled charge-coupled
device CH250 detector (Photometrics). The computer with this microscope uses
IPLab software (Scanalytics), which provides control of excitation filters and
image acquisition. The brightest pixels in an image were below saturation, and
some images were contrast enhanced for display purposes but were qualitatively
reflective of unprocessed data collected from the original image(s).
Statistical analysis. The Kaplan-Meier product limit test was used to measure
significant differences between survival curves (GraphPad Prism software).
All other samples were subject to a Student t test and are represented as the
means  the standard errors of the mean (SEM).
RESULTS
Immunization with the type I cps1-1 strain elicits long-term
immunity to lethal type II infection in genetically susceptible
C57BL/6 mice. We measured the ability of the cps1-1 vaccine
strain to elicit immune protection against lethal type II infec-
tion. One month after immunization, immunized and age-
matched naive mice were infected with either a nonlethal (10-
cyst) or lethal (100-cyst) dose of the type II strain ME49 by the
i.p. or i.g. route, and survival was monitored. Mice immunized
with the cps1-1 strain completely survived both doses of chal-
lenge regardless of route (Fig. 1A and B). As expected, naive
mice infected with the nonlethal challenge of 10 cysts survived
and naive mice infected with the lethal 100 cyst dose suc-
cumbed to infection (Fig. 1A and B).
Due to the high potency of immunization with the cps1-1
vaccine in protecting mice against high-dose type I and type II
lethal challenge infections and induction of long-lasting immu-
nity to type I challenge (14, 20), we measured the durability of
cps1-1 strain-induced protective immunity against type II chal-
lenge. Ten months after immunization, immunized and age-
matched naive mice were infected with either a nonlethal (10-
cyst) or lethal (100-cyst) dose of the type II strain ME49 by the
i.p. or i.g. route, and survival was monitored. cps1-1 strain-
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immunized mice completely survived both doses of challenge
regardless of the challenge route (Fig. 1C and D). In contrast,
only 50% of nonimmunized mice that were age matched to
those that had been immunized survived the 10-cyst challenge
when given i.p., most likely due to the loss of immune
function with age (Fig. 1C). Age-matched 10-month-old un-
immunized mice did not survive the lethal 100-cyst chal-
lenge (Fig. 1C and D).
Vaccination with the cps1-1 strain significantly reduces the
brain cyst and parasite burden after type II challenge infec-
tion but does not prevent establishment of chronic infection.
C57BL/6 mice are genetically highly susceptible to type II
infections in that they acquire higher brain cyst burdens during
acute infection, and these cysts ultimately recrudesce and
cause lethal toxoplasmic encephalitis during chronic infection
(3, 7, 10, 23, 41, 52). Thus, we measured cyst burdens and
parasite burden in brains of cps1-1 strain-immunized or naive
mice 5 weeks after ME49 challenge infection. Naive mice (1
month age-matched), challenged with 10 cysts i.p. or i.g., con-
tained 4,130  490 cysts and 2,730  380 cysts per brain,
respectively (Fig. 2A). Immunized mice, challenged with 10
cysts either i.p. or i.g., had significantly (P  0.0001 and P 
0.0001) fewer cysts per brain compared to naive mice (170 
30 and 10  6, respectively) (Fig. 2A). Immunized mice chal-
lenged at 10 months postimmunization showed similar reduc-
tions in cyst burden and exhibited brain cyst burdens of 106 
48.3 cysts (i.p.) and 275  140 cysts (i.g.), respectively, com-
pared to naive mice challenged with 10 cysts i.p. or i.g. that
exhibited brain cyst burdens of 10,633 638 and 3,800 1625,
respectively (Fig. 2C). Interestingly, cps1-1 strain-immunized
mice challenged with a lethal high cyst dose (100 cysts) at
either 1 month or 10 months postimmunization survived acute
infection and exhibited a decrease in brain cysts similar to that
observed with the 10-cyst dose challenges.
During the course of our cyst enumeration, we observed
brain cysts of various sizes under light microscopy. Conse-
quently, a real-time PCR assay was used to determine absolute
parasite burdens in brain tissue based on measurement of
genomes or parasite equivalents (PE) (see Materials and
Methods). As previously observed (20, 26), unchallenged
cps1-1 strain-immunized mice exhibited no detectable PE in
the blood, spleen, and brain, indicating that the cps1-1 strain
does not replicate or develop mature cysts and is cleared be-
fore challenge is administered (data not shown). Naive mice
contained 871.6  13.7 or 626.9  292.8 PE per 400 ng of total
brain DNA when challenged at 1 month by either the i.p. or the
i.g. route, respectively (Fig. 2B). Naive mice challenged at 10
months contained 881.9  75.8 (i.p.) and 593.1  151.2 (i.g.)
PE, respectively, per 400 ng of brain DNA (Fig. 2D). In con-
trast, cps1-1 strain-immunized mice challenged 1 month after
immunization contained 28.8  6.2 (i.p.) PE (P  0.001) and
30.8  16.5 (i.g.) PE (P 0.001) (Fig. 2B). Mice challenged 10
months after immunization contained 69.3 7.3 (i.p.) PE (P
0.001) and 12.4  4.9 (i.g.) PE (P  0.01) (Fig. 2D). Despite
the significant immune protection afforded after immunization
with cps1-1, these observations revealed that a population of
ME49 parasites was still capable of trafficking to the brain and
establishing a chronic infection with a reduced cyst burden.
Adoptive transfer of immune splenocytes to a type II T.
gondii-infected mouse enhances control of chronic infection.
Vaccination with the cps1-1 strain is highly effective at promot-
ing survival to acute infection, as well as reducing cyst burdens
and parasite numbers in chronic infection in mice challenged
with type II ME49 cysts. The immune control mechanisms
elicited by cps1-1 strain vaccination could prevent tachyzoites
from trafficking to brain, could promote bradyzoite or cyst
development, could eradicate existing brain cysts, or could
prevent parasite access to the brain. In type I RH challenge
infection, immunity elicited by the cps1-1 strain shows a pow-
erful effect and rapidly clears tachyzoites (20, 26). To establish
FIG. 1. Immunization with the cps1-1 vaccine elicits long-lasting immunity against a lethal type II challenge regardless of the immunization
route. C57BL/6 mice were either not immunized or immunized i.p. with 106 cps1-1 tachyzoites given twice 14 days apart. One month later (A and
B) or 10 months later (C and D) naive mice were challenged i.p. (E) or i.g. (), and cps1-1 strain-immunized mice were challenged i.p. (‚) or
i.g. (✳) with either 10 (A and C) or 100 (B and D) ME49 cysts. The percent survival was monitored for 5 weeks, at which time the experiment
was stopped. The data represent the results of one experiment with six mice per group.
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a kinetic of parasite recrudescence, genetically susceptible B6
mice were infected with 10 ME49 cysts i.p., the brains were
harvested, and the cysts were enumerated at weeks 5, 5.5, and
7 postinfection. As shown in Fig. 3A, cyst burdens decreased
overtime and higher numbers were found at week 5 compared
to week 7. To measure the ability of cps1-1 strain-induced
immunity to target established brain cysts, total splenocytes
were adoptively transferred into mice with established ME49
chronic infections. B6 mice were infected with 10 ME49 cysts
i.p., and then at 3.5 or 5 weeks after infection mice received
either no treatment, 5  107 whole naive splenocytes, or 5 
107 whole cps1-1 strain-immune splenocytes. At 2 weeks after
adoptive transfer of total splenocytes, the brains were har-
vested, and the cysts were enumerated. Treatments conducted
at 3.5 weeks after ME49 infection showed no significant dif-
ferences in the brain cyst burden (Fig. 3B) or parasite burden
(Fig. 3C). In contrast, treatments conducted at 5 weeks after
ME49 infection showed significant differences in brain cyst
burden (Fig. 3B) and parasite burden (Fig. 3C). Mice receiving
naive splenocytes or no treatment showed nearly identical cyst
and parasite burden reductions compared to week 3.5 treat-
ment groups. Remarkably, mice receiving cps1-1 strain-im-
mune splenocytes exhibited significantly higher brain cyst bur-
den (Fig. 3B), as well as higher parasite burdens compared to
naive or no treatment groups (Fig. 3C). However, compared to
the week 5 cyst burdens shown in the kinetic analysis (Fig. 3A),
the cyst numbers were only slightly reduced. The parasite bur-
den (Fig. 3C) correlated well with the cyst burden (Fig. 3B),
but we observed an increase in the average cyst diameter in
light microscopy (data not shown) and an increase in parasite
units (Fig. 3D). These observations indicated that adoptive
transfer of the cps1-1 strain-immune splenocytes could delay or
prevent cyst recrudescence in chronic infection and cysts con-
tinue to develop.
To define which cell type in cps1-1 strain-immune spleno-
cytes was preventing recrudescence of brain cysts, purified
CD4, CD8, or CD4 and CD8 T cells from cps1-1 strain-
immunized or naive mice were adoptively transferred into mice
infected with 10 ME49 cysts 5 weeks earlier, and then the
brains were harvested 2 weeks later to enumerate the cyst
burden. Mice receiving naive CD4, CD8, CD4 CD8, or
immune CD4 T cells were not statistically different in brain
cyst burden of 1,945  254, 2,200  826, 1,519  298, or
2,531  767, respectively (Fig. 4). In contrast, mice receiving
immune CD8 T cells or a combination of immune CD4 and
CD8 T cells had significantly higher cyst burdens (5,006 
705 and 3,891  368, respectively) (Fig. 4) compared to naive
controls. The cyst burdens in mice receiving immune CD8 T
cells were not different from those measured at week 5 as
shown in Fig. 3A. These results suggest that cps1-1 strain-
immune CD8 T cells delay or prevent cyst recrudescence in
chronic infection.
C57BL/6 mice immunized with cps1-1 strain do not succumb
to chronic type II ME49 infection. Type II strain T. gondii-
FIG. 2. Short-term and long-term immunity induced by the cps1-1 strain prevents cyst formation. C57BL/6 mice were either not immunized or
immunized i.p. with 106 cps1-1 tachyzoites twice 14 days apart. One month and ten months after cps1-1 vaccine administration, age-matched naive (f)
and immune (u) mice were challenged with 10 cysts of ME49 i.p. or i.g. At 5 weeks after challenge infection, cyst enumeration was performed in the brains
of the mice challenged 1 month (A) and 10 months (C) after final immunization. Brain parasite burdens were measured by real-time quantitative PCR
of the T. gondii B1 gene in mice challenged 1 month (B) and 10 months (D) after final the immunization. The data represent the means the SEM from
one experiment with six mice per group. Statistical differences were calculated by using the Student t test, and P 	 0.001 was considered significant (*
for the i.p.-challenged group and ** for the i.g.-challenged group).
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infected C57BL/6 mice invariably succumb to complications
associated with either recrudescent disease or the damage in-
curred during the acute stage of infection typically sometime
after 12 weeks of infection (3, 18, 21, 34). Sensitivity to type II
T. gondii infection is clearly dependent on the mouse genotype
(3, 7, 10, 23, 41, 52) and, as recently proposed, may be specif-
ically related to immunodominant H-2Ld-restricted MHC-I
epitopes found within GRA6, GRA4, and ROP7 proteins (6,
16). We examined whether cps1-1 strain immunization would
prolong the survival of susceptible C57BL/6 mice challenged
long term with 10 cysts of ME49 i.p. The cps1-1 strain-immu-
nized mice survived chronic infection for at least 12 months
after ME49 infection. In contrast, naive mice rapidly suc-
cumbed to chronic ME49 infection (Fig. 5).
cps1-1 tachyzoites begin to differentiate into bradyzoites
during uracil starvation. Recent data show that the nonrepli-
cating cps1-1 strain elicits a strong local and systemic IL-12 p70
response that is more typical of a type II strain than a type I
strain (20), and cytolytic CD8 T cells develop with faster
kinetics compared to infection with replicating parasites (26).
Previous studies also suggest that T. gondii life-stage-specific
CD8 T-cell responses are important for control of the para-
site (16, 30, 39). We examined the expression pattern of
tachyzoite-stage marker (SAG1) and an early-bradyzoite-stage
marker (CST1) during uracil starvation of the cps1-1 strain.
While replicating cps1-1 parasites expressed SAG1 at high
levels and did not express CST1 bradyzoite marker (Fig. 6, top
panels), uracil starvation induced a nearly complete loss of
FIG. 3. Immune splenocytes from cps1-1 strain-immunized mice
prevents cyst recrudescence. C57BL/6 mice were either not immunized
or immunized i.p. with 106 cps1-1 tachyzoites twice given 14 days apart.
Separately, susceptible C57BL/6 mice were infected i.p. with 10 cysts of
ME49 to establish chronic infection. (A) Brains were harvested from
chronically infected mice at weeks 5, 5.5, and 7 postinfection as indi-
cated, and the cysts were enumerated. (B, C, and D) Chronically
infected mice received no treatment (), naive splenocytes (f), or
immune splenocytes (u) from cps1-1 strain-immunized mice at 3.5 or
5 weeks after ME49 infection. At 2 weeks after adoptive transfer, the
cysts were enumerated (B), the parasite burdens (PE) were calculated
by using quantitative real-time PCR of the T. gondii B1 gene (C), and
the parasite units were calculated as PE per 400 ng of brain tissue
DNA per cyst (D). The data represent the means  the SEM from a
group of five animals; the experiment was repeated twice. Statistical
differences were calculated by using the Student t test, and P	 0.05 (*)
was considered significant.
FIG. 4. CD8 T cells from cps1-1 strain-immunized mice prevent
cyst recrudescence. C57BL/6 mice were either not immunized or im-
munized i.p. with 106 cps1-1 tachyzoites given twice 14 days apart.
Separately, genetically susceptible C57BL/6 mice were infected i.p.
with 10 cysts of ME49 to establish chronic infection. Chronically in-
fected mice received naive (u) or immune (f) CD4, CD8, or CD4
CD8 T cells isolated from cps1-1 strain-immunized mice at 5 weeks
after ME49 infection. At 2 weeks after adoptive transfer, the cysts were
enumerated. The data represent the means  the SEM from a group
of five animals; the experiment was repeated twice. Statistical differ-
ences were calculated by using the Student t test, and P 	 0.05 (*) was
considered significant.
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expression of SAG1 and markedly upregulated the expression
of CST1 (Fig. 6, bottom panels). These data suggest that an
altered profile of tachyzoite and early bradyzoite antigens oc-
curs within 2 days of initiating uracil starvation of the cps1-1
strain.
DISCUSSION
These studies extend a series of recent and significant re-
ports that have examined the immune responses elicited by
vaccination with the attenuated cps1-1 strain (13, 14, 20, 35, 49,
51, 56–59). To our knowledge, this is the first report that
vaccination of genetically susceptible C57BL/B6 mice with a
type I strain can prevent the development of lethal chronic
infection.
A potent and long-lasting immunity to lethal type 1 infection
is elicited by a single cps1-1 strain immunization of BALB/c,
C57BL/6, Tyk2/ (C57BL/6), or MyD88/ (C57BL/6) mice
(13, 14, 20, 49, 51, 56). Immunity to lethal type I challenge
infection induced by the cps1-1 strain is dependent on CD8 T
cells (20) and the local production of IFN- (20) and IL-12 p70
(20, 51, 56) and, surprisingly, does not require significant pro-
duction of systemic IFN- (20).
Previous studies of the durability of immunity elicited by
immunization with type I strain ts-4 or by infection with type II
parasite strains in susceptible B6 mice suggest that immunity
significantly wanes over time (8, 18, 27, 33, 47). Protecting
highly genetically susceptible B6 mice from lethal acute or
lethal chronic type II infection by vaccination is problematic. If
parasites traffic to the brain or other tissues before the immune
response can prevent cyst formation, it is currently unknown
whether any immune response can clear preexisting cysts. Many
studies have documented that B6 mice (MHC-I-restricted H-2b
background) are extremely susceptible to type II infections (10,
23, 52). If these mice survive acute type II infection, then they
will invariably succumb from the chronic infection within a
few months. Recently, the GRA6 protein of type II strains
was shown to possess an immunodominant H-2Ld-restricted
MHC-I cell epitope that appears to play a major role in pro-
tecting BALB/c mice from lethal chronic infection. In addition,
GRA4 and ROP7 have been characterized as containing life-
stage-specific dominant epitopes (16). Since these epitopes are
not recognized in B6 mice, loss of immune response to these
immunodominant epitopes may at least partly explain the in-
creased susceptibility of B6 mice to lethal type II chronic in-
fections (6).
Interestingly, the immunodominant H-2Ld-restricted MHC-I
epitope HF10 within the GRA6 protein of type II strains is not
present in type I strains such as RH from which the cps1-1 and
ts-4 vaccine strains are derived (14, 45). Our results show that
immunization of B6 mice with the cps1-1 strain completely
protects mice from lethal type II cyst challenge (i.p. or i.g.
route) at 1 month (short term) and equally well at 10 months
(long term). These results suggest that adaptive immunity di-
rected against the immunodominant H-2Ld-restricted MHC-I
epitope within the GRA6 protein of type II strains is not
FIG. 5. Immunization with the cps1-1 strain prevents lethality of
chronic infection in the genetically sensitive C57BL/6 mouse strain.
C57BL/6 mice were either not immunized or immunized i.p. with 106
cps1-1 tachyzoites given twice 14 days apart. At 1 month after immu-
nization, naive mice (}) or cps1-1 strain-immunized mice () were
challenged with 10 cysts of ME49 i.p., and the percent survival was
monitored. The data represent the results of one experiment per-
formed with 10 animals per group.
FIG. 6. Uracil starvation of the cps1-1 strain induces the loss of tachyzoite-stage antigens and the expression of early-bradyzoite-stage antigens.
Confluent HFF monolayers were infected with cps1-1 tachyzoites in the presence (top panels) or absence (bottom panels) of uracil for 2 days.
Immunohistochemistry analysis was performed after fixation of infected HFF monolayers with DAPI (blue), anti-P30/SAG1 (green), and
DBA/CST1 (red) as indicated. The images show the results with DAPI alone (left panels, top and bottom), anti-P30/SAG1 alone (left center
panels, top and bottom), DBA/CST1 alone (right center panels, top and bottom), and merged DAPI/SAG1/DBA (right panels, top and bottom).
The images contain the brightest pixels below saturation, are unprocessed, and were collected from the original image(s).
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necessary for control of acute lethal type II infections delivered
by the i.p. or i.g. route in B6 mice.
Immune control of chronic infection in regard to whether
mice succumb or survive is clearly multifaceted and highly
dependent on both genetic factors and parasite genotype. Our
results with immunization of genetically susceptible B6 mice
with the cps1-1 strain show that mice challenged with a suble-
thal acute infection dose of ME49 cysts at 1 month or 10
months postimmunization exhibit remarkably reduced levels of
brain cyst burden and brain parasite burden and that these
chronically infected B6 mice survive significantly longer than
chronically infected naive mice. Our results show that a ster-
ilizing immunity to brain cyst formation is not generated in
cps1-1 strain-immunized mice. The simplest explanation of
these results is that type II infections can rapidly elicit new
brain cysts early after oral infection and prior to immune de-
struction of tachyzoite stages. Several studies have suggested
that cysts may develop early after infection since cysts contain-
ing only a few bradyzoites have been observed (55). Consider-
ing the potent immune responses elicited after cps1-1 strain
immunization, it seems likely that parasites emerging from
challenge cysts most likely traffic to the brain early during
infection or possibly after each wave of cellular infection be-
fore immune control of tachyzoite-stage infection is fully rees-
tablished by the recall response to cps1-1 strain immunity (49).
A significant fraction of cps1-1 strain-elicited immunity is
clearly targeted to tachyzoite stages based on rapid clearance
of tachyzoite challenge (20, 26). Our experiments do not spe-
cifically address whether cps1-1 strain-elicited immunity to
type II infection is directed against tachyzoite- or bradyzoite-
stage antigens. Several studies show that tachyzoite-stage an-
tigens and bradyzoite-stage antigens induce potent stage-spe-
cific CD8 T-cell responses important for the control of T.
gondii infection (16, 30, 39). Our results suggest that antigens
from both stages may play a role in the more potent immunity
induced by the cps1-1 strain compared to the ts-4 strain. The
cps1-1 strain vaccine is delivered in the tachyzoite stage but
within 2 days of uracil starvation begins to differentiate to early
bradyzoite stages with a corresponding loss of tachyzoite-stage
antigens. Although our results show that the cps1-1 strain may
elicit T-cell responses to both stages, our data do not discrim-
inate whether early bradyzoite antigen expression or the loss of
tachyzoite-stage antigens contributes to the potent protective
immunity induced by the cps1-1 strain. In addition, our study
did not determine whether cps1-1 strain-induced immunity is
solely tachyzoite stage specific or both tachyzoite and brady-
zoite stage specific. Because the cps1-1 strain is completely
nonreplicating (compared to ts-4), the immune response elic-
ited by cps1-1 strain vaccination may favor better control of
type II infection. Recent results suggest there is markedly less
inflammation induced by the cps1-1 vaccine model and the
cytokine response to the cps1-1 strain more closely resembles
that of a type II strain (20).
Autophagy could also play a role in the more potent immu-
nity elicited by cps1-1 vaccination. Vaccination with the cps1-1
strain elicits potent autophagy responses in B6 mice (35, 57–
59). Consequently, if the cps1-1 strain ultimately delivers “self-
autophagic” responses and the nonreplicating cps1-1 parasite
and its associated vacuole is digested in an autophagosome, a
wider repertoire and/or increased presentation of parasite an-
tigens may occur after immunization with cps1-1. Our data do
not differentiate between these possibilities or other potential
mechanisms that could explain the potent protection against
type II infection elicited in C57BL/6 mice by the cps1-1 vac-
cine.
Interestingly, our results show that CD8 T cells elicited by
the cps1-1 vaccine have a direct effect on the outcome of
chronic infection in the brain. cps1-1 strain-elicited immune
CD8 T cells prevent the recrudescence of already-established
brain cysts in B6 mice. Cysts that were prevented from recru-
descing by cps1-1 immunity continued to develop. These data
do not distinguish whether these T cells recognize tachyzoite-
or bradyzoite-stage antigens, and this mechanistic question will
be addressed in future studies. Regardless of the mechanism of
action, immune CD8 T cells elicited by cps1-1 strain vaccina-
tion delay or prevent cyst recrudescence, and this clearly cor-
relates with prolonged survival of chronically infected B6 mice.
This immune control is independent of the H-2Ld-restricted
GRA6, GRA4, and ROP7 derived epitopes and suggests that
other factors and antigens are required to control chronic infec-
tion in cps1-1 strain-immunized B6 mice. Our data suggest this
immune control may be due to bradyzoite-stage antigens ex-
pressed by the cps1-1 strain during uracil starvation, but we can-
not yet rule out the possibility that the increased control of type II
infection observed in our study is due to tachyzoite-stage antigens
other than GRA6, GRA4, and ROP7.
In summary, we demonstrate that the cps1-1 vaccine is highly
effective at inducing both short-term and long-term protection
against type II parasite challenge by significantly inhibiting
lethal acute and lethal chronic disease in genetically suscepti-
ble C57BL/6 mice. CD8 T cells elicited by cps1-1 vaccination
delay or prevent cyst recrudescence in chronically infected B6
mice. These studies further establish that the live attenuated
cps1-1 vaccine strain is an excellent vaccine that confers sig-
nificant protection against both type I and type II strains of T.
gondii. The cps1-1 vaccination model represents a valuable tool
in which to further dissect the complex biology of how control
of chronic infection is won or lost in C57BL/6 and other ge-
netic backgrounds.
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